Teva Pharmaceutical Industries on Monday responded to Mylan’s letter of last week, saying that, contrary to doing little more than “meddling,” its offer to buy the generic drugmaker was “strong and serious.”
Teva’s more than $40 billion proposal “offers exceptional opportunity for Mylan’s and Teva’s stockholders and other stakeholders, and deserves careful review and engagement by your board and your stockholders,” CEO Erez Vigodman wrote to Mylan executive chairman Robert Coury.
The two companies have been sparring since April, when Teva offered to buy Mylan for $82 a share. Mylan rejected the offer and instead is trying to acquire over-the-counter drugmaker Perrigo, which has also been reluctant to merge.
In a letter to Mr. Vigodman last week, Mr. Coury accused Israel-based Teva of “playing games” by pushing an “illusionary” buyout offer that has no chance of going through.
“There is nothing unclear or equivocal about Teva’s intentions,” Mr. Vigodman said in his letter Monday. “We have a clear roadmap to deliver on our proposal.”
Mr. Vigodman also said that contrary to Mylan’s assertion, Teva’s 2.2 percent stake in its rival — which Teva accumulated recently by buying shares on the open market — does not violate U.S. antitrust laws.
Read More
“We have conferred with the U.S. antitrust authorities and have been given no reason to believe that our purchases violate the Hart-Scott-Rodino Act or any other U.S. antitrust laws,” he said.
Generic drugmaker Mylan is run from Cecil, Washington County, but reincorporated in the Netherlands earlier this year.
“We note that you have been saying you are a Dutch company when you believe it helps you create unprecedented governance structures, a U.K. company when it helps you lower your U.S. taxes and a U.S. company when you believe it helps you prevent Teva from purchasing Mylan shares,” Mr. Vigodman said.
He also accused Mylan of having “made grossly incorrect statements about Teva to mislead your stockholders and other stakeholders about us.”
Mylan released a brief letter replying to Mr. Vigodman on Monday, saying his letter failed to answer key questions, including whether Teva planned to make a “legally binding exchange offer” for Mylan.
Mylan officials have said they are planning a special shareholders meeting in the third quarter to seek approval to buy Perrigo. Although Perrigo’s board has rejected the offer, Mylan plans to take the bid directly to that company’s shareholders.
Teva has said if the Perrigo transaction goes through, it won’t acquire Mylan.
Patricia Sabatini: psabatini@post-gazette.com or 412-263-3066.



Comments
Welcome to Post-Gazette subscriber-only commenting community. Please review our community guidelines.